Michael Morse, MD
Enriched profileProfessor of Medicine (Medical Oncology), Professor in the Department of Surgery · Duke University School of Medicine
Michael Morse is Professor of Medicine (Medical Oncology), Professor in the Department of Surgery at Duke University School of Medicine. OpenAlex indexes 552 publications with 28,410 citations (h-index 82); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Michael A. Morse, MD, is Professor of Medicine (Medical Oncology), Professor in the Department of Surgery at Duke University School of Medicine / Duke Cancer Institute. The public record shows 552 publications with 28,410 citations (h-index 82), centered on Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 33 companies, 3 NIH-funded awards (2001–2008).
- Most recent indexed publication: 2025 · Science immunology
- Top research focus: Immunotherapy and Immune Responses
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 283.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Duke University
- Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines
Sponsor: Duke University
- Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
Sponsor: Duke University
Industry payments
Updated 14 Oct 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202598 payments$96,438openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202551 payments$77,963openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year202546 payments$68,763openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
49.3%Serotonin-3 Receptor Antagonist32.6%Ondansetron Hcl100%Part D≥21 patientsPotassium supplement8.7%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
35.5%Kinase inhibitor35.5%Imatinib Mesylate76%Cabometyx25%Part D<11 patientsNervous system
15.2%Phenothiazine15.2%Prochlorperazine Maleate100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
3 NIH research awards on record, funded 2001–2008 per NIH RePORTER. The latest:
Congress activity
Updated 14 Oct 2026
114 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells
AACR Annual Meeting
AACR2024Co-author - Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.
ASCO Annual Meeting
ASCO2024Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity.
Science immunology
Article2025 - Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.
CA: a cancer journal for clinicians
Review2025 - Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET).
Journal of neuroendocrinology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-morse-md-dccc1472
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
netrf.org/specialist/dr-michael-morse-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →netrf.org ↗ - Other
onclive.com/authors/michael-morse-md-duke-cancer-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board Certified
Hematology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
Expert Opinion on Biological Therapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - Associate Editor
Clinical Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - Associate Editor
Cancer Investigation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Kraus, MD
Duke University School of Medicine
Angeles Secord, MD
Duke University School of Medicine
Virginia Kraus, MD, PhD
Duke University School of Medicine
Neal Ready, MD
Duke University School of Medicine
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH